Cardiovascular Risk in Chronic Inflammatory Biomarkers

Beyond the Joints

It is a common misconception that diseases like Rheumatoid Arthritis and Psoriatic Arthritis are confined entirely to the musculoskeletal system. Accumulating epidemiological data indicates that systemic inflammation inherently drives accelerated atherogenesis, placing rheumatology patients at a significantly higher risk for cardiovascular disease (CVD) than the general public.

The Pathophysiological Connection

Chronic elevation of pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha, Interleukin-1 (IL-1), and Interleukin-6 (IL-6), does not just cause synovial inflammation. It actively destabilizes vascular endothelial function, promotes plaque formation, and alters lipid metabolism.

Systemic Cytokines (TNF-α, IL-6) ➔ Endothelial Dysfunction ➔ Accelerated Plaque Formation ➔ Increased CVD Risk

• The "Inflammatory Paradox": Traditional lipid panels can sometimes be deceptively low or normal in patients with active, untreated systemic inflammation, masking their true cardiovascular risk.

• Cardioprotective Therapy: Interestingly, aggressive control of systemic inflammation using methotrexate or TNF inhibitors has been shown to simultaneously reduce the risk of major adverse cardiovascular events (MACE).

According to a consensus statement published in The Lancet Rheumatology, regular cardiovascular risk screening, lifestyle modifications, and optimized tight-control anti-inflammatory therapy must be integrated into the standard care protocol for all patients with chronic inflammatory arthritis.

Source: www.jacc.org/doi/10.1016/j.jcmg.2021.09.014